| Patent application number | Description | Published |
|---|
| 20080262040 | Chemical Compounds - The invention is directed to novel indazole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I): | 10-23-2008 |
| 20090069318 | Novel Compounds - Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors. | 03-12-2009 |
| 20090163589 | Calcilytic Compounds - Novel calcilytic compounds and methods of using them are provided. | 06-25-2009 |
| 20090197871 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics - The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis. | 08-06-2009 |
| 20090203657 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics - The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, | 08-13-2009 |
| 20090203677 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics - The present invention relates to novel compounds of Formula (I) | 08-13-2009 |
| 20090239897 | NOVEL COMPOUNDS - Novel substituted 1,5,7-trisubstituted-1,8-napthyridin-2(1H)-one compounds; 1,5,7 trisubstituted-1,6-napthyridine-2-(1H)-one compounds and 1,5,7-trisubstituted quinoline-2(1H)-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy. | 09-24-2009 |
| 20110054021 | Calcilytic Compounds - Novel calcilytic compounds and methods of using them are provided. | 03-03-2011 |
